2,914 material Form 8-K filings that 2,352 companies we cover made with the SEC in August 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Santander Holdings USA reported second-quarter 2026 net income of $585 million, up 41.2% from the prior quarter and 17.5% from a year earlier, in a fixed income investor presentation furnished under Items 2.02 and 7.01. The filing also said the Federal Reserve approved the acquisition of Webster Financial Corporation on August 4, 2026, and that the deal is now expected to close on August 20, 2026.
Q2 2026 net income of $585 million, up 41.2% from Q1 2026 and up 17.5% from Q2 2025
Net interest income of $1.5 billion, up 1.7% from Q1 2026 and up 2.7% from Q2 2025
Federal Reserve approved the Webster Financial acquisition on August 4, 2026; closing expected August 20, 2026
CET1 ratio of 13.7% at June 30, 2026, up from 13.0% in Q1 2026
CuriosityStream reported second-quarter 2026 revenue of $23.2 million, up from $19.0 million a year earlier, with net income of $8.9 million compared with $0.8 million. The company raised its full-year 2026 revenue and adjusted EBITDA guidance and declared a $0.085 quarterly dividend, which matters to shareholders because it reflects higher reported profit and a higher outlook.
Q2 2026 revenue was $23.2 million, up 22% from $19.0 million in Q2 2025; licensing revenue was $14.1 million, up 48%.
Q2 2026 net income was $8.9 million, or $0.15 per diluted share, versus $0.8 million in Q2 2025; adjusted EBITDA was $11.4 million versus $3.0 million.
Full-year 2026 revenue guidance is $77 million to $82 million, and full-year adjusted EBITDA guidance is $18 million to $22 million.
Quarterly dividend of $0.085 per share is payable September 18, 2026, to holders of record on September 4, 2026.
On August 7, 2026, Radiant Logistics entered into an amended and restated $200 million secured revolving credit facility with Bank of America as administrative agent, replacing a credit agreement dated August 5, 2022. The company says the new facility lowers borrowing costs, removes the credit spread adjustment, extends maturity to 2031 and enlarges the accordion to $100 million. For shareholders, the filing shows more borrowing capacity and new terms, with the company stating it had no net debt as of March 31, 2026.
Facility size is $200 million, with a five-year term maturing August 7, 2031
Pricing is SOFR plus 137.5 to 212.5 basis points, a reduction from the prior facility
Accordion feature increased from $75 million to $100 million for future acquisitions
Covenants require a maximum net leverage ratio of 3.0x and a minimum interest coverage ratio of 3.0x; as of March 31, 2026, $25.0 million was drawn and $39.6 million in cash was on hand
Mexco Energy reported net income of $501,065 for the quarter ended June 30, 2026, up 107% from a year earlier, and operating revenues rose 13% to $1,983,169. Revenue growth came mainly from a 52% higher average oil price, partly offset by a 15% drop in oil production, which matters to shareholders because the company's earnings depend on both prices and output.
Net income was $501,065, or $0.24 per diluted share, versus $241,951, or $0.12 per diluted share, in the prior-year quarter.
Operating revenues were $1,983,169, up 13% from $1,756,940, driven by a 52% increase in average oil price.
Oil production fell 15% and natural gas production fell 9%, while the average natural gas price fell 49%.
The company spent approximately $2.1 million on oil and gas royalty property acquisitions, funded from existing cash, and expects drilling and completion costs of approximately $1.8 million for the fiscal year ending March 31, 2027.
EquipmentShare reported second-quarter 2026 revenue of $1,449 million, up 26% from a year earlier, with net income of $19 million compared with $16 million. Diluted earnings per share were $0.06 in both periods, and the company reiterated its 2026 outlook, which projects total revenue of $5,254 million to $5,682 million and Adjusted Core EBITDA of $1,946 million to $2,058 million.
Q2 2026 total revenue $1,449 million, up 26% from $1,147 million; Rental Segment revenue $908 million, up 39%
Net income $19 million vs. $16 million a year earlier; GAAP diluted EPS $0.06 in both periods
Adjusted Core EBITDA $531 million, up 34% from $395 million; includes $24 million of IPO Founders Awards stock compensation excluded from Adjusted Net Income
2026 outlook: total revenue $5,254 million to $5,682 million; Adjusted Core EBITDA $1,946 million to $2,058 million
Crown Crafts reported first-quarter fiscal 2027 net sales of $16.8 million and net income of $2.1 million, compared with a net loss of $1.1 million a year earlier. Gross profit was helped by $3.7 million in tariff refunds, and the Board declared a $0.03 per share quarterly dividend. Stockholders also approved an amended 2021 Incentive Plan that raises the share reserve to 2,450,000 shares.
Net sales rose to $16.8 million from $15.5 million in the prior-year quarter ended June 29, 2025.
Net income was $2.1 million, or $0.19 per share, versus a net loss of $1.1 million, or $0.10 per share, a year earlier.
Gross profit included $3.7 million in tariff refunds; excluding refunds, gross margin was 25.6%, up 290 basis points year over year.
The $0.03 per share dividend is payable October 2, 2026 to holders of record on September 11, 2026.
StubHub reported second-quarter 2026 revenue of $573.1 million, up 33% from a year earlier, and net income of $14.6 million compared with a net loss of $53.8 million in the prior-year quarter. The company raised its full-year 2026 gross merchandise sales (GMS) outlook to $10.1 billion to $10.3 billion and reiterated its adjusted EBITDA outlook of $400 million to $420 million, which signals improved operating results for shareholders.
Revenue of $573.1 million, up 33% from $430.3 million; GMS of $3.1 billion, up 34%
Net income of $14.6 million versus a net loss of $53.8 million a year earlier; adjusted EBITDA of $105.7 million, up 94%
Full-year 2026 GMS outlook raised to $10.1 billion to $10.3 billion; adjusted EBITDA outlook of $400 million to $420 million reiterated
Free cash flow of $309.7 million versus $9.7 million; year-to-date debt reduction of $200.0 million
FGI Industries reported second-quarter 2026 revenue of $31.9 million, up 2.9% from a year earlier, with gross margin rising to 33.4% from 28.1%. The company posted net income attributable to shareholders of $1.3 million, or $0.65 per diluted share, compared with a loss of $1.2 million, or $0.64 per diluted share, a year earlier. The company reaffirmed its fiscal 2026 guidance, which includes total net revenue of $134-141 million.
Q2 2026 revenue was $31.9 million, up 2.9% year over year; gross profit was $10.7 million, up 22.5%.
Operating income was $1.4 million, compared with an operating loss of $0.8 million in Q2 2025.
Diluted EPS was $0.65 versus a loss of $0.64 a year earlier; cash was $4.4 million and total liquidity was $7.9 million at June 30, 2026.
Fiscal 2026 guidance was reaffirmed, with total net revenue of $134-141 million and adjusted operating income of $0.7-2.5 million.
Resideo reported second quarter 2026 revenue of $1.98 billion, up 2% year over year, with net income of $97 million versus a net loss of $825 million a year earlier and diluted EPS of $0.51. The company also completed the spin-off of ADI Global Distribution on August 3, 2026, and named Shane Harrison Senior Vice President and Chief Financial Officer effective September 1, 2026.
Q2 2026 adjusted EPS was $0.83, up 26% from a year earlier, and adjusted EBITDA was $249 million, up 19%.
GAAP income from operations fell 26% to $131 million, with $31 million of business separation costs in the quarter.
Resideo initiated standalone outlook: third quarter 2026 revenue of $705 million to $730 million and full-year 2026 revenue of $2.90 billion to $2.95 billion.
EnerSys reported first quarter fiscal 2027 net sales of $935.6 million, up 4.8% from a year earlier, and GAAP diluted EPS of $3.09 versus $1.46. Adjusted diluted EPS of $3.66 came in above the company's May 20 guidance range of $2.80 to $2.90. The Board also raised the quarterly dividend 10% to $0.2875 per share, and the company guided second quarter net sales to $955 million to $995 million.
Net sales of $935.6 million, up 4.8% from $893.0 million; GAAP diluted EPS of $3.09 versus $1.46.
Adjusted diluted EPS of $3.66, above the $2.80 to $2.90 guidance range; results include $30.9 million of tariff refunds.
Second quarter fiscal 2027 outlook: net sales of $955 million to $995 million and adjusted diluted EPS of $3.15 to $3.25.
Quarterly dividend raised 10% to $0.2875 per share, payable October 2, 2026, to holders of record as of September 18, 2026.
Gaxos.ai reported record second-quarter 2026 revenue of $2.46 million, up 35.8% from the first quarter and up 1,337% from the second quarter of 2025, while advertising and marketing expense rose about 13.5%. GAAP net income was $241,056, or $0.02 per share, mainly from a gain on the sale of its gaming assets to Game Foundry AI, so the profit may not repeat in future quarters. The filing gives no financial guidance for future periods.
Q2 2026 revenue was $2.46 million, up 35.8% from $1.81 million in Q1 2026 and up 1,337% from $0.17 million in Q2 2025.
GAAP net income was $241,056, or $0.02 per basic and diluted share, primarily reflecting a gain from the gaming asset sale.
Advertising and marketing expense was $3,141,273 in Q2, compared with $2,766,824 in Q1 2026.
Cash and short-term investments were about $11.44 million at June 30, 2026, versus $11.71 million at March 31, 2026.
Atea Pharmaceuticals reported a narrower second-quarter net loss of $32.9 million, down from $37.2 million a year earlier, as lower research and development and general and administrative spending more than offset lower interest income. Cash and investments fell from $301.8 million at December 31, 2025 to $219.5 million at June 30, 2026. The release also restates the July C-BEYOND Phase 3 results and gives timing for C-FORWARD topline data and a planned new drug application, which shape the company's path to a possible US launch of BEM/RZR.
Net loss of $32.9 million, or $0.41 per share, for the three months ended June 30, 2026, versus $37.2 million, or $0.44 per share, a year earlier.
Research and development expenses fell to $28.2 million from $32.3 million; general and administrative expenses fell to $7.0 million from $9.1 million.
Cash, cash equivalents and marketable securities were $219.5 million at June 30, 2026, down from $301.8 million at December 31, 2025.
C-FORWARD Phase 3 topline results are expected in early first quarter 2027; a new drug application submission is anticipated in the second quarter of 2027.
Allogene Therapeutics reported a second-quarter 2026 net loss of $42.7 million, or $0.13 per share, compared with $50.9 million, or $0.23 per share, a year earlier. The company also reported $423.6 million in cash, cash equivalents and investments as of June 30, 2026, and said that cash should fund operations into 2029. The filing furnishes a press release that also gives an update on its pivotal ALPHA3 trial of cema-cel in large B-cell lymphoma, including an interim MRD clearance result and FDA designations.
Second-quarter 2026 collaboration revenue from a related party was $4.6 million, versus none a year earlier.
Net loss was $42.7 million for the quarter ended June 30, 2026, versus $50.9 million in the same quarter of 2025.
Guidance: 2026 operating expense is expected to be about $165 million, and GAAP operating expenses about $225 million, excluding potential business development activity.
In the interim analysis, 58.3% (7/12) of cema-cel arm patients achieved MRD negativity versus 16.7% (2/12) in the observation arm; the FDA granted RMAT and Fast Track designations in July.
Acrivon Therapeutics reported a second-quarter 2026 net loss of $18.0 million, down from $21.0 million a year earlier, as research and development and general and administrative expenses declined. The company said its cash, cash equivalents and investments of $90.0 million are expected to fund operations into the fourth quarter of 2027. The company also reiterated that interim data from the ACR-368 Phase 2b study are expected in the second half of 2026.
Net loss per share was $0.43 for the quarter ended June 30, 2026, versus $0.55 a year earlier.
Research and development expenses were $13.8 million, versus $16.2 million; the company said two ACR-368 milestones achieved in 2025 did not recur in 2026.
General and administrative expenses were $4.8 million, versus $6.5 million, mainly due to lower employee-related expenses, including stock-based compensation.
Cash, cash equivalents and investments totaled $90.0 million as of June 30, 2026.
Coherent reported fourth-quarter fiscal 2026 revenue of $2.05 billion, up 34% from a year earlier, and GAAP diluted earnings of $1.19 per share, compared with a loss of $0.83 per share in the same quarter last year. The company also guided first-quarter fiscal 2027 revenue to $2.2 billion to $2.4 billion and non-GAAP EPS to $1.85 to $2.05.
Q4 fiscal 2026 revenue was $2.05 billion, up 34% year over year and up 13.3% from the prior quarter.
GAAP gross margin was 38.5%, up 277 basis points year over year; non-GAAP gross margin was 40.2%.
Q4 non-GAAP diluted EPS was $1.74, up $0.74 from $1.00 a year earlier.
Q1 fiscal 2027 guidance: revenue of $2.2 billion to $2.4 billion and non-GAAP EPS of $1.85 to $2.05.
Cisco reported fiscal fourth-quarter 2026 revenue of $17.3 billion, up 18% year over year, with GAAP diluted EPS of $0.97 and non-GAAP EPS of $1.22, up 52% and 23%. It also issued fiscal 2027 guidance of $72.2 billion to $73.4 billion in revenue and $5.05 to $5.11 in non-GAAP EPS, both of which shareholders will weigh against the stronger fiscal 2026 results.
Q4 FY 2026 revenue was $17.3 billion, up 18%; GAAP net income was $3.9 billion and non-GAAP net income was $4.9 billion.
FY 2027 guidance: revenue $72.2 billion to $73.4 billion; GAAP EPS $4.00 to $4.06; non-GAAP EPS $5.05 to $5.11.
Q1 FY 2027 guidance: revenue $18.0 billion to $18.2 billion; non-GAAP EPS $1.32 to $1.34.
Quarterly dividend of $0.42 per share declared, payable October 21, 2026, to holders of record on October 2, 2026.
Journey Medical reported second-quarter 2026 revenue of $18.5 million, up 23% from $15.0 million a year earlier, with Emrosi contributing $8.1 million. The GAAP net loss narrowed to $0.3 million, or $0.01 per share, from $3.8 million, or $0.16 per share, in the prior-year quarter. The filing gives no financial guidance, and the company reported $25.6 million in cash at June 30, 2026.
Total revenue of $18.5 million for the quarter ended June 30, 2026, up 23% from $15.0 million
Emrosi revenue of $8.1 million in the quarter; total prescriptions were approximately 36,000, up from approximately 30,000 in the first quarter of 2026
GAAP net loss of $0.3 million, or $(0.01) per share, versus $3.8 million, or $(0.16) per share, a year earlier
Cash and cash equivalents of $25.6 million at June 30, 2026; gross margin was 67%, consistent with the prior-year quarter
Liftoff Mobile reported second-quarter 2026 revenue of $220 million, up 35% from a year earlier and 7% from the first quarter. The company posted a net loss of $4 million, compared with a $24 million loss a year earlier and $49 million of net income in the first quarter, and it said the loss includes $45 million of non-cash IPO-related expenses. The filing also gives third-quarter and full-year 2026 guidance for revenue and Adjusted EBITDA.
Q2 2026 revenue was $220 million, up 35% year over year and 7% quarter over quarter.
Net loss was $4 million, versus a $24 million loss in Q2 2025 and net income of $49 million in Q1 2026.
Adjusted EBITDA was $132 million, up 55% year over year, with a 60% margin.
Guidance: Q3 2026 revenue of $217 million to $222 million; full-year 2026 revenue of $870 million to $880 million.
Lumexa Imaging reported second quarter 2026 revenue of $264.2 million, up 5.1% from a year earlier, and net income of $2.7 million, compared with a net loss of $7.2 million in the same quarter of 2025. The company reiterated its full-year 2026 revenue guidance and narrowed its Adjusted EBITDA range to $235 million to $241 million, leaving the midpoint at $238 million.
Q2 2026 revenue of $264.2 million vs. $251.4 million; system-wide revenue growth of 6.0%
Net income of $2.7 million, or $0.03 per diluted share, vs. a net loss of $7.2 million a year earlier
Adjusted EBITDA of $56.4 million vs. $56.3 million; Adjusted EBITDA margin fell to 21.4% from 22.4%
Full-year 2026 guidance: revenue $1.045 billion to $1.097 billion (reiterated); Adjusted EPS $0.71 to $0.77 (reiterated)
STAAR Surgical reported second-quarter 2026 results for the quarter ended July 3, 2026, with net sales of $93.5 million, up from $44.3 million a year earlier, and net income of $8.1 million, or $0.16 per diluted share, compared with a net loss of $16.8 million a year earlier. The filing furnishes the earnings release as Exhibit 99.1 and announces a conference call at 5:30 p.m. Eastern on August 12, 2026, where management will discuss the results. The company reported cash and investments of $181.5 million and no outstanding debt.
Net sales of $93.5 million, up 111% year over year; sales excluding China were $41.2 million, up 6.0%
China sales of $52.3 million; EMEA sales declined by a low single-digit percentage, with growth excluding the Middle East
Net income of $8.1 million, or $0.16 per diluted share, versus a net loss of $16.8 million, or $0.34 per diluted share, a year ago
Adjusted EBITDA of $20.0 million, or $0.39 per diluted share; cash and investments of $181.5 million at July 3, 2026
Hyperion DeFi reported second-quarter 2026 GAAP net income of $31.0 million, up from $8.8 million in the first quarter, driven mainly by $54.8 million in treasury gains as the HYPE token price rose. The company reiterated its 2026 guidance of $5 million to $7 million in Adjusted Gross Profit and said it still expects Adjusted Net Operating Cash Flow to turn positive by the end of 2026, but operating cash flow remained negative at $2.1 million in the quarter.
GAAP net income was $31.0 million in Q2 2026 versus $8.8 million in Q1 2026; diluted EPS was $0.92 versus $0.26.
Adjusted Gross Profit rose 20% quarter over quarter to $1.15 million from $960 thousand.
Treasury gains were $54.8 million as HYPE price rose to $65.0 from $36.6; Gross HYPE Tokens reached 2.04 million.
2026 guidance of $5 million to $7 million in Adjusted Gross Profit was reiterated, and Adjusted Net Operating Cash Flow was ($2.1 million) in Q2 2026.
Usio reported second quarter 2026 revenue of $23.7 million, up 19% from a year earlier, and swung to GAAP net income of about $0.3 million, or $0.01 per share, from a net loss of $0.4 million a year earlier. The company raised its full-year 2026 revenue growth expectation to 14% to 16%, from 10% to 12% previously, which signals higher expected top-line growth for shareholders.
Q2 2026 revenue was $23.7 million, up 19% from $20.0 million in Q2 2025.
GAAP net income was about $0.3 million, or $0.01 per share, versus a net loss of $0.4 million, or $0.01 per share, a year earlier.
Adjusted EBITDA was $1.1 million, compared with $0.5 million in the same quarter of 2025.
Full-year 2026 revenue is now expected to rise 14% to 16%; cash was $6.4 million at June 30, 2026, down $1.0 million since December 31, 2025.
On August 6, 2026, subsidiary Capitala Business Lending entered a sixth amendment to its KeyBank senior secured revolving credit facility. The amendment increases the facility from $75.0 million to $150.0 million, lowers the applicable margin, and extends the reinvestment period and maturity. Proceeds were used to repay in full a separate JPMorgan Chase facility held by Great Lakes Portman Ridge Funding LLC, which was then terminated.
Facility amount increases from $75.0 million to $150.0 million.
Applicable margin falls to 2.50% per annum from 2.80% in the reinvestment period, and to 3.00% from 3.20% in the amortization period.
Reinvestment period extended from August 21, 2027 to August 6, 2029; maturity extended from August 21, 2029 to August 6, 2031.
Borrowings repaid the JPMorgan Chase revolving facility in full, and its financing commitments were terminated.
Alkermes plc entered into Amendment No. 1 to its credit agreement dated February 12, 2026, with JPMorgan Chase Bank as administrative agent. The amendment lowers the interest rate spread by 0.75% on the term loan A facility and by 0.50% on the term loan B facility, among other changes. The filing does not report earnings or other operating results, so its direct effect on shareholders is limited to lower borrowing costs on the company's term loans.
Term loan A outstanding principal: $745,312,500, maturing February 12, 2031
Term loan B outstanding principal: $773,062,500, maturing August 12, 2031
Spread reduced 0.75% on term loan A and 0.50% on term loan B
Amendment dated August 12, 2026, filed as Exhibit 10.1
Definium Therapeutics announced positive topline results from Voyage, its first Phase 3 study of DT120 ODT in generalized anxiety disorder, meeting its primary and all key secondary efficacy endpoints. The filing reports a placebo-adjusted HAM-A change of 5.4 points at Week 12 (p<0.0001) and states the drug was generally well tolerated, with no new safety signals identified. The results support the company's development program, but the filing does not describe any regulatory approval, and the second Phase 3 GAD study, Panorama, is expected to report topline results in September 2026.
Primary endpoint: HAM-A change of -11.6 for DT120 ODT versus -6.2 for placebo at Week 12, a difference of -5.4 points (p<0.0001)
Study enrolled 214 participants across approximately 35 U.S. sites; 107 received DT120 ODT and 107 received placebo in the reported highlights
Company reported no suicidality signal or suicidal behavior; the average time to meet end-of-session criteria was 6.4 hours
Panorama, the second Phase 3 GAD study, has a topline readout anticipated in September 2026
Brinker reported fourth-quarter fiscal 2026 total revenues of $1,535.8 million, up from $1,461.9 million, and net income per diluted share of $2.99, up from $2.30. The company guided fiscal 2027 total revenues to $6.15 billion-$6.27 billion and non-GAAP diluted EPS to $12.60-$13.40, and its board authorized an additional $718.0 million in share repurchases, bringing total available authority to $750.0 million.
Q4 fiscal 2026 total revenues $1,535.8 million vs $1,461.9 million; comparable restaurant sales up 5.0%, with Chili's up 5.6%
Fiscal 2027 guidance includes a 53rd operating week, which the company estimates adds about 2.0% to total revenues and $0.70 to non-GAAP diluted EPS
Board authorized up to an additional $718.0 million in buybacks on August 10, 2026, for total authority of $750.0 million
Xilio Therapeutics reported second quarter 2026 results, with collaboration and license revenue rising to $18.7 million from $8.1 million a year earlier and the net loss narrowing to $6.4 million from $15.8 million. The company also said the FDA cleared its IND application for XTX501, and it expects existing cash to fund operations into the first quarter of 2028.
Collaboration and license revenue was $18.7 million for the quarter ended June 30, 2026, compared with $8.1 million a year earlier, driven by agreements with AbbVie and Gilead.
Net loss was $6.4 million, compared with $15.8 million for the same quarter of 2025.
The FDA cleared the IND application for XTX501 to proceed to a Phase 1/2 trial; dosing in the Phase 1 portion is expected in the second half of 2026.
Cash and cash equivalents were $136.0 million as of June 30, 2026, with runway expected into the first quarter of 2028.
Local Bounti reported second-quarter 2026 sales of $13.9 million, up 14% from $12.1 million a year earlier, and a net loss of $19.8 million, down from $21.6 million. Adjusted EBITDA loss narrowed 17% to $5.8 million, while gross profit fell to $1.0 million from $1.5 million. The company also disclosed a $12.5 million investment from an existing strategic investor after quarter end, and it said the results are preliminary because its Form 10-Q has not been filed.
Sales were $13.9 million, up 14% from $12.1 million a year earlier and up 4% from $13.3 million in the first quarter of 2026.
Net loss was $19.8 million versus $21.6 million; adjusted EBITDA loss was $5.8 million versus $7.1 million.
Gross profit was $1.0 million versus $1.5 million; adjusted gross margin was 27% versus 30%.
After June 30, 2026, an existing strategic investor provided $12.5 million via a convertible note and warrant; cash and restricted cash were $10.1 million at June 30, 2026.
Performance Food Group reported fourth-quarter fiscal 2026 net sales up 6.4% to $18.0 billion and net income up 23.4% to $162.3 million, with full-year net income up 5.6% to $359.3 million. The company also issued fiscal 2027 guidance of $72.5 billion to $73.0 billion in net sales and $2.125 billion to $2.225 billion in Adjusted EBITDA, which is useful context for shareholders assessing the year ahead.
Q4 fiscal 2026 diluted EPS rose 22.6% to $1.03, while Adjusted Diluted EPS rose 2.6% to $1.59
Full-year fiscal 2026 net sales rose 7.2% to $67.8 billion and diluted EPS rose 5.0% to $2.29
Fiscal 2027 guidance: Q1 net sales of $17.9 billion to $18.1 billion; full-year Adjusted EBITDA of $2.125 billion to $2.225 billion
As of June 27, 2026, $498.5 million remained available under the share repurchase program
Protalix reported second-quarter 2026 total revenue of $19.9 million, up from $15.7 million a year earlier, and net income of $3.8 million, or $0.05 per share, compared with $164,000 in the same quarter of 2025. The company reaffirmed its full-year 2026 total revenue outlook of $78.0 million to $83.0 million, which includes a $25.0 million Chiesi milestone already received, and reported $40.7 million in cash and short-term deposits at June 30, 2026.
Q2 2026 total revenue was $19.9 million versus $15.7 million in Q2 2025; sales of goods rose $4.4 million to $19.8 million, driven mainly by sales to Chiesi and Fiocruz (Brazil).
Net income for the six months ended June 30, 2026 was $22.1 million, or $0.27 per diluted share, compared with a net loss of $3.5 million a year earlier; the period includes the $25.0 million Chiesi milestone.
2026 guidance reiterated: total revenue of $78.0 million to $83.0 million, with Elfabrio sales excluding milestones of $33.0 million to $35.0 million and Elelyso sales of $20.0 million to $23.0 million.
Top-line results from the PRX-115 Phase 2 RELEASE trial are anticipated in the second half of 2027.
Kontoor Brands reported second-quarter 2026 revenue of $584 million, up 19% from a year earlier, and adjusted earnings per share of $1.06, up 13%. The company raised its full-year 2026 adjusted EPS outlook to $5.25 to $5.35 and plans to put $400 million of Lee divestiture proceeds into an accelerated share repurchase after that sale closes in the fourth quarter. For shareholders, the higher outlook and planned buyback point to expected profit growth and capital return, though reported diluted EPS from continuing operations slipped to $1.03 from $1.05.
Revenue of $584 million rose 19%, including $114 million from Helly Hansen; Wrangler revenue rose 2%.
Adjusted EPS of $1.06 rose 13%; reported diluted EPS from continuing operations was $1.03 versus $1.05 a year earlier.
Full-year 2026 adjusted EPS outlook raised to $5.25 to $5.35 from $5.15 to $5.25; revenue outlook unchanged at $2.66 to $2.71 billion.
Planned $400 million accelerated share repurchase, funded by Lee divestiture proceeds, expected after the sale closes in the fourth quarter.
Liquidia reported second quarter 2026 results for the period ended June 30, 2026, with total revenue of $171.7 million and net income of $74.7 million, or $0.74 per diluted share, compared with a net loss of $41.6 million a year earlier. The company also filed an updated corporate presentation for healthcare conferences and analyst meetings.
Net product sales of YUTREPIA were $170.4 million in the second quarter of 2026, up 31% from the first quarter of 2026
Net income was $74.7 million, or $0.74 per diluted share, versus a net loss of $41.6 million, or $0.49 per share, in the second quarter of 2025
Cash and cash equivalents were $284.2 million as of June 30, 2026, compared with $190.7 million as of December 31, 2025
Research and development expenses rose to $17.2 million and SG&A expenses rose to $57.4 million for the quarter
Bio-Techne reported fourth-quarter fiscal 2026 revenue of $321.2 million, up 1% as reported and 3% organic, with GAAP EPS of $0.35 versus a loss of $0.11 a year earlier. Adjusted EPS was $0.52, down from $0.53, and full-year adjusted EPS rose to $1.93 from $1.92 on flat revenue of $1.2 billion. The company said it will no longer hold quarterly investor calls because of its pending acquisition by Merck KGaA, Darmstadt, Germany, at $73 per share in cash.
Q4 fiscal 2026 net sales were $321.2 million, up 1% reported and 3% organic.
Q4 GAAP EPS was $0.35 versus $(0.11) a year earlier; adjusted EPS was $0.52 versus $0.53.
Full-year fiscal 2026 net sales were flat at $1.2 billion; full-year adjusted EPS was $1.93 versus $1.92.
Board declared an $0.08 per share dividend, payable September 4, 2026, to holders of record on August 24, 2026.
Amcor reported fourth-quarter fiscal 2026 net sales of $6.4 billion, up 26% largely from the Berry acquisition, and net income of $389 million versus a loss of $39 million a year earlier. Adjusted EPS was $1.23, up 23%, and full-year adjusted EPS was $4.02, up 13%. The company guided to adjusted EPS of $1.80 to $1.90 for the six-month transition period ending December 31, 2026, and declared a quarterly dividend of 65.0 cents per share.
Q4 net income $389 million vs. a $39 million loss a year earlier; diluted EPS $0.83 vs. -$0.10
Q4 adjusted EBITDA $1,045 million, up 32%; adjusted EPS $1.23 vs. $1.00, up 23%
Full-year net sales $23.5 billion, up 57%, largely driven by the Berry acquisition
Transition period (July 1 to December 31, 2026) adjusted EPS outlook of $1.80 to $1.90; quarterly dividend 65.0 cents per share, payable September 24, 2026
National Vision reported second quarter 2026 net revenue up 2.5% to $498.8 million, with net income rising to $12.4 million from $8.7 million and diluted EPS of $0.15 versus $0.11. The company raised its fiscal 2026 adjusted operating income outlook to $119 million-$139 million, but lowered the top of its adjusted comparable store sales growth range to 3.0%-5.0% from 3.0%-6.0%.
Q2 2026 net revenue rose 2.5% to $498.8 million; net income was $12.4 million versus $8.7 million a year earlier.
Adjusted operating income rose 32.7% to $31.6 million; adjusted operating margin was 6.3% versus 4.9%.
Fiscal 2026 adjusted operating income outlook raised to $119 million-$139 million from $107 million-$133 million.
Adjusted comparable store sales growth outlook narrowed to 3.0%-5.0% from 3.0%-6.0%; the company repurchased 1.2 million shares for $20.0 million in the quarter.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.